Abstract：
OBJECTIVE: This study aimed to further evaluate the potential value of Pan-Immune-Inflammation Value (PIV) as a prognostic marker in patients with laryngeal and pharyngeal tumors.
METHODS: A total of 545 patients with laryngeal and pharyngeal tumors who underwent surgery at Qilu Hospital of Shandong University were included. We determined the optimal cutoff of PIV and divided the patients into two groups. The relationship between PIV and clinicopathological features was explored by the chi-square test and the Mann-Whitney U test. Survival analysis and Cox regression analysis were used to evaluate the relationship between PIV and overall survival (OS) and disease-free survival (DFS). We also compared the prognostic predictive value of PIV with other inflammation-related markers. Finally, we developed a simple scoring prediction model based on several independent prognostic parameters.
RESULTS: We found that PIV was statistically associated with clinicopathological features such as tumor stage (p < 0.001), node stage (p = 0.001), postoperative chemotherapy (p = 0.026), and vascular thrombosis (p = 0.027). Survival analysis demonstrated a significant correlation between elevated PIV and reduced OS and DFS (p < 0.0001). Multivariate Cox regression analysis further confirmed PIV as a prognostic indicator (HR 2.507; 95% CI 1.343-4.681; p = 0.004), which is superior to SII, NLR, MLR and PLR. Three of the independent prognostic factors screened by multivariate Cox regression analysis were selected to be used to create a scoring system with a concordance index of 0.756.
CONCLUSIONS: Elevated PIV is associated with poor prognosis in patients with laryngeal and pharyngeal tumors, suggesting that PIV may be an important adjunctive indicator for assessing patient prognosis.
UNASSIGNED: Registration number: KYLL-202307-001, date: July 2023.
METHODS: A total of 545 patients with laryngeal and pharyngeal tumors who underwent surgery at Qilu Hospital of Shandong University were included. We determined the optimal cutoff of PIV and divided the patients into two groups. The relationship between PIV and clinicopathological features was explored by the chi-square test and the Mann-Whitney U test. Survival analysis and Cox regression analysis were used to evaluate the relationship between PIV and overall survival (OS) and disease-free survival (DFS). We also compared the prognostic predictive value of PIV with other inflammation-related markers. Finally, we developed a simple scoring prediction model based on several independent prognostic parameters.
RESULTS: We found that PIV was statistically associated with clinicopathological features such as tumor stage (p < 0.001), node stage (p = 0.001), postoperative chemotherapy (p = 0.026), and vascular thrombosis (p = 0.027). Survival analysis demonstrated a significant correlation between elevated PIV and reduced OS and DFS (p < 0.0001). Multivariate Cox regression analysis further confirmed PIV as a prognostic indicator (HR 2.507; 95% CI 1.343-4.681; p = 0.004), which is superior to SII, NLR, MLR and PLR. Three of the independent prognostic factors screened by multivariate Cox regression analysis were selected to be used to create a scoring system with a concordance index of 0.756.
CONCLUSIONS: Elevated PIV is associated with poor prognosis in patients with laryngeal and pharyngeal tumors, suggesting that PIV may be an important adjunctive indicator for assessing patient prognosis.
UNASSIGNED: Registration number: KYLL-202307-001, date: July 2023.
摘要：
目的：本研究旨在进一步评估泛免疫-炎症值（PIV）作为喉部和咽部肿瘤患者预后标志物的潜在价值。
方法：选择在山东大学齐鲁医院接受手术治疗的喉咽部肿瘤患者545例。我们确定了PIV的最佳截止值，并将患者分为两组。通过卡方检验和Mann-WhitneyU检验探讨PIV与临床病理特征之间的关系。采用生存分析和Cox回归分析评价PIV与总生存期(OS)和无病生存期(DFS)的关系。我们还比较了PIV与其他炎症相关标志物的预后预测价值。最后,我们基于几个独立的预后参数建立了一个简单的评分预测模型.
结果：我们发现PIV与临床病理特征如肿瘤分期有统计学关联（p<0.001），节点阶段(p=0.001)，术后化疗（p=0.026），血管血栓形成（p=0.027）。生存分析显示PIV升高与OS和DFS降低之间存在显著相关性(p<0.0001)。多因素Cox回归分析进一步证实PIV是预后指标(HR2.507;95%CI1.343-4.681;p=0.004),优于SII，NLR,MLR和PLR。通过多变量Cox回归分析筛选出的独立预后因素中的三个被选择用于创建一致指数为0.756的评分系统。
结论：喉部和咽部肿瘤患者PIV升高与预后不良相关，提示PIV可能是评估患者预后的重要辅助指标。
■注册号：KYLL-202307-001，日期：2023年7月。
方法：选择在山东大学齐鲁医院接受手术治疗的喉咽部肿瘤患者545例。我们确定了PIV的最佳截止值，并将患者分为两组。通过卡方检验和Mann-WhitneyU检验探讨PIV与临床病理特征之间的关系。采用生存分析和Cox回归分析评价PIV与总生存期(OS)和无病生存期(DFS)的关系。我们还比较了PIV与其他炎症相关标志物的预后预测价值。最后,我们基于几个独立的预后参数建立了一个简单的评分预测模型.
结果：我们发现PIV与临床病理特征如肿瘤分期有统计学关联（p<0.001），节点阶段(p=0.001)，术后化疗（p=0.026），血管血栓形成（p=0.027）。生存分析显示PIV升高与OS和DFS降低之间存在显著相关性(p<0.0001)。多因素Cox回归分析进一步证实PIV是预后指标(HR2.507;95%CI1.343-4.681;p=0.004),优于SII，NLR,MLR和PLR。通过多变量Cox回归分析筛选出的独立预后因素中的三个被选择用于创建一致指数为0.756的评分系统。
结论：喉部和咽部肿瘤患者PIV升高与预后不良相关，提示PIV可能是评估患者预后的重要辅助指标。
■注册号：KYLL-202307-001，日期：2023年7月。
